Comments
Cadila Healthcare today said that Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals USA, has received final approval from the US health regulator to market Dextroamphetamine Sulfate and Amphetamine Sulfate tablets.
Nesher has received final approval from the United States Food and Drug Administration (USFDA) to market the tablets in the strengths of 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg, 20 mg and 30 mg, the Zydus Group firm said in a filing to BSE.
The drug will be produced at Nesher’s manufacturing facility at St Louis, MO, USA. The tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy, Cadila said.
The group now has over 165 approvals and so far filed more than 300 abbreviated new drug applications (ANDAs) since the commencement of the filing process, it added.
Shares of Cadila Healthcare, the listed entity of the group, were trading at Rs 507.70 per scrip on BSE, up 2.01 per cent from their previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.